CMS says Medicare pays 16% more than private insurers for lab tests. Preliminary 2027 rates could save $1B a year, with cuts capped at 15%. Craig-Hallum flags code confusion at GeneDx, Adaptive and Myriad, but says the WGS drop looks overdone.
Natera launches Zenith Genomics — its next-generation whole-genome sequencing test for faster rare disease diagnosis. GeneDx shares drop 8% as competition intensifies in the rare-disease market, which carries a $1 trillion economic burden.
Wells Fargo upgrades GeneDx to Overweight, saying the recent stock decline looks excessive and growth opportunities could drive momentum into 2026.
